- Home
- ECBK vs PRQR Comparison
ECBK vs PRQR Comparison
Compare ECBK & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECBK | PRQR |
|---|---|---|
| Founded | 1919 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.3M | 167.5M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ECBK | PRQR |
|---|---|---|
| Price | $16.90 | $1.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 7.2K | ★ 273.3K |
| Earning Date | 04-23-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $18.88 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.55 | $1.08 |
| 52 Week High | $20.05 | $3.10 |
Technical Indicators
Market Signals| Indicator | ECBK | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 40.14 |
| Support Level | $15.86 | $1.33 |
| Resistance Level | $16.53 | $1.58 |
| Average True Range (ATR) | 0.45 | 0.11 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 13.53 | 5.56 |
Price Performance
Historical ComparisonAbout ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.